The FDA has cleared the IND for oremepermin alfa in the United States. While an additional Phase III trial continues in Japan, preparations are being accelerated to initiate Phase III in the U.S. Orphan Drug Designation is maintained. This represents a new global development milestone and is expected to expand opportunities for funding.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4884-20261019-01.pdf","jir_short_summary":"The FDA has cleared the IND for oremepermin alfa in the United States. While an additional Phase III trial continues in Japan, preparations are being accelerated to initiate Phase III in the U.S. Orphan Drug Designation is maintained. This represents a new global development milestone and is expected to expand opportunities for funding.","jir_summary":"### News Overview\nKringle Pharma, Inc. announced FDA IND clearance in the United States for oremepermin alfa, targeting the acute phase of spinal cord injury. While progressing an additional Phase III trial in Japan, the company will accelerate preparations to commence clinical development in the U.S. and expects to expand fundraising opportunities, including strategic partnerships and non-dilutive capital. This is positioned as an important milestone for global expansion.\n\n### Outlook and Impact\nIND clearance marks a new phase in global development and will strengthen collaboration with clinical development partners toward initiating Phase III trials in the U.S. This increases the likelihood of providing a new treatment option for patients in the acute phase of spinal cord injury and is expected to enhance corporate value. Expanded opportunities to secure development funding are anticipated, supporting a strengthened financial strategy that may include non-dilutive financing.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KringlePharma, #SpinalCordInjuryTherapeutic, #INDClearance","jir_key_figures":"IND clearance (FDA): Unknown\nAdditional Phase III trial: Ongoing (Japan)\nOrphan Drug Designation: Maintained in Japan, U.S., and EU","jir_meta_title":"Kringle Pharma Announces FDA IND Clearance for oremepermin alfa, Accelerating Global Development | October 2026","jir_meta_description":"Kringle Pharma announces FDA IND clearance for oremepermin alfa. The company continues an additional Phase III trial in Japan and is preparing to start clinical development in the U.S., while retaining Orphan Drug Designation and expecting expanded funding opportunities.","jir_og_title":"FDA IND Clearance Advances Global Development of oremepermin alfa | Kringle Pharma","jir_og_description":"Kringle Pharma announced FDA IND clearance for oremepermin alfa. The company is preparing to initiate Phase III in the U.S., aiming to expand global development and funding opportunities.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-132423","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n